Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Erez Israeli, CEO of Dr Reddys Laboratories, said that the company has no plans to shift manufacturing to the US unless it ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddys Laboratories reports 2% rise in net profit to Rs 1,418 crore on higher expenses, revenue up 11% Disclaimer: The ...

The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).